Search Results

By Dave Levitan  / October 10, 2024

ASCO Updates Stage III NSCLC Guideline to Include Osimertinib in Wake of LAURA Trial Data

ASCO has issued a rapid update to its guideline on the management of stage III non–small cell lung cancer (NSCLC), based on the results of the phase III LAURA trial, which was presented at the 2024 ASCO Annual Meeting and published simultaneously in The New England Journal of Medicine.1,2 The...